Hyperoxaluria - Pipeline Review, H1 2016

Published: May, 2016 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Hyperoxaluria - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Hyperoxaluria - Pipeline Review, H1 2016', provides an overview of the Hyperoxaluria pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hyperoxaluria and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperoxaluria
- The report reviews pipeline therapeutics for Hyperoxaluria by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Hyperoxaluria therapeutics and enlists all their major and minor projects
- The report assesses Hyperoxaluria therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Hyperoxaluria

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Hyperoxaluria
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Hyperoxaluria pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Hyperoxaluria Overview 7
Therapeutics Development 8
Pipeline Products for Hyperoxaluria - Overview 8
Hyperoxaluria - Therapeutics under Development by Companies 9
Hyperoxaluria - Pipeline Products Glance 10
Clinical Stage Products 10
Early Stage Products 11
Hyperoxaluria - Products under Development by Companies 12
Hyperoxaluria - Companies Involved in Therapeutics Development 13
Allena Pharmaceuticals, Inc. 13
Alnylam Pharmaceuticals, Inc. 14
Dicerna Pharmaceuticals, Inc. 15
Digna Biotech, S.L. 16
OxThera AB 17
Hyperoxaluria - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
ALLN-177 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
ALLN-230 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
ALN-GO1 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
DB-027 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
DCR-PH - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
DCRPH-1 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Oxabact - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
Hyperoxaluria - Recent Pipeline Updates 38
Hyperoxaluria - Dormant Projects 42
Hyperoxaluria - Discontinued Products 43
Hyperoxaluria - Product Development Milestones 44
Featured News & Press Releases 44
May 13, 2016: Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-PH1 in Patients with Primary Hyperoxaluria Type 1 44
May 05, 2016: FDA Grants Orphan Drug Designation to Allena's Investigational Therapy for the Treatment of Pediatric Hyperoxaluria 45
Feb 10, 2016: Allena Pharmaceuticals Initiates Patient Treatment in Third Phase 2 Trial of ALLN-177 for Secondary Hyperoxaluria 45
Dec 21, 2015: Dicerna Begins Dosing in First Clinical Trial of Therapy for Primary Hyperoxaluria Type 1 in Healthy Volunteers 46
Nov 12, 2015: Allena Pharmaceuticals Announces Presentation of Successful Phase 2 Data from ALLN-177 Program at American Society of Nephrology Kidney Week 48
Nov 04, 2015: Allena Pharmaceuticals to Present Phase 2 Data on ALLN-177 Program at ASN Kidney Week 2015 49
Sep 02, 2015: Dicerna Pharmaceuticals Submits Investigational New Drug Application for DCR-PH1, an Investigational Therapy for Primary Hyperoxaluria Type 1 (PH1) 49
Aug 06, 2015: EMA Grants Orphan Drug Designation to DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 50
Aug 04, 2015: Allena Pharmaceuticals Initiates Phase 2b Trial of ALLN-177 for Secondary Hyperoxaluria 50
Apr 23, 2015: FDA Grants Orphan Drug Designation for DCR-PH1, Dicerna's Investigational Therapy for the Treatment of Primary Hyperoxaluria Type 1 (PH1) 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53

List of Tables

Number of Products under Development for Hyperoxaluria, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Hyperoxaluria - Pipeline by Allena Pharmaceuticals, Inc., H1 2016 13
Hyperoxaluria - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 14
Hyperoxaluria - Pipeline by Dicerna Pharmaceuticals, Inc., H1 2016 15
Hyperoxaluria - Pipeline by Digna Biotech, S.L., H1 2016 16
Hyperoxaluria - Pipeline by OxThera AB, H1 2016 17
Assessment by Monotherapy Products, H1 2016 18
Number of Products by Stage and Target, H1 2016 20
Number of Products by Stage and Mechanism of Action, H1 2016 22
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Hyperoxaluria Therapeutics - Recent Pipeline Updates, H1 2016 38
Hyperoxaluria - Dormant Projects, H1 2016 42
Hyperoxaluria - Discontinued Products, H1 2016 43